Clinical Trial Update: An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum [Phase 2]

View source ↗

Summary

An extension Phase 2 study evaluating the long-term safety and tolerability of JNJ-54861911 in participants with early Alzheimer's disease. The trial was termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• JNJ-54861911

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Alzheimer Disease | Phase 2 | Status: TERMINATED | Results posted: 2019-09-09